Detection of HER2 Status in Breast Cancer: Comparison of Current Methods with MLPA and Real-time RT-PCR |
Pazhoomand, Reza
(Genetics Research Center)
Keyhan, Elahe (Genetics Research Center) Banan, Mehdi (Genetics Research Center) Najmabad, Hossein (Genetics Research Center) Karimlou, Masoud (Department of Biostatistics and Computer Sciences, University of Social Welfare and Rehabilitation Sciences) Khodadad, Faranak (Department of Surgery, Mehrad Hospital) Iraniparast, Alireza (School of Medicine, Shiraz University of Medical Sciences) Feiz, Farnaz (School of Medicine, Shiraz University of Medical Sciences) Majidzadeh, Keivan (Cancer Genetics Research Group, Breast Cancer Research Center, ACER) Bahman, Ideh (Genetics Research Center) Moghadam, Fatemeh Aghakhani (Genetics Research Center) Sobhani, Atoosa Madadkar (Department of Biostatistics and Computer Sciences, University of Social Welfare and Rehabilitation Sciences) Abedin, Seyedeh Sedigheh (Genetics Research Center) Muhammadnejad, Ahad (Cancer Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences) Behjat, Farkhondeh (Genetics Research Center) |
1 | Babu GR, Samari G, Cohen SP, et al (2011). Breast cancer screening among females in Iran and recommendations for improved practice: a review. Asian Pac J Cancer Prev, 12, 1647-55. |
2 | Baehner FL, Achacoso N, Maddala T, et al (2010). Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories. J Clin Oncol, 28, 4300-6. DOI ScienceOn |
3 | Barberis M, Pellegrini C, Cannone M, et al (2008). Quantitative PCR and HER2 testing in breast cancer: a technical and cost-effectiveness analysis. Am J Clin Pathol, 129, 563-70. DOI ScienceOn |
4 | Barrett C, Magee H, O'Toole D, Daly S, Jeffers M (2007). Amplification of the HER2 gene in breast cancers testing 2+ weak positive by HercepTest immunohistochemistry: false-positive or false-negative immunohistochemistry? J Clin Pathol, 60, 690-3. DOI ScienceOn |
5 | Blackwell KL, Burstein HJ, Storniolo AM, et al (2010). Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumabrefractory metastatic breast cancer. J Clin Oncol, 28, 1124-30. DOI ScienceOn |
6 | Bloom K, Harrington D (2004). Enhanced accuracy and reliability of HER-2/neu immunohistochemical scoring using digital microscopy. Am J Clin Pathol, 121, 620-30. DOI |
7 | Collins R, Xiang D, Christie A, et al (2012). Comparison of HER2 expression by immunohistochemistry (IHC) using automated imaging system and fluorescence in situ hybridization (FISH). A retrospective analysis of 2853 cases. Cancer Res, 72, 4. DOI |
8 | Criscitiello C, Curigliano G (2013). HER2 signaling pathway and trastuzumab cardiotoxicity. Future Oncol, 9, 179-81. DOI ScienceOn |
9 | Cui J, Germer K, Wu T, et al (2012). Cross-talk between HER2 and MED1 regulates tamoxifen resistance of human breast cancer cells. Cancer Res, 72, 5625-34. DOI ScienceOn |
10 | Del Mastro L, Lambertini M, Bighin C, et al (2012). Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients. Expert Rev Anticancer Ther, 12, 1391-405. DOI |
11 | Dolan M, Snover D (2005). Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice. Am J Clin Pathol, 123, 766-70. DOI ScienceOn |
12 | Gutierrez C, Schiff R (2011). HER2: biology, detection, and clinical implications. Arch Pathol Lab Med, 135, 55-62. |
13 | Farolfi A, Melegari E, Aquilina M, et al(2013). Trastuzumabinduced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors. Heart, 99, 634-9. DOI ScienceOn |
14 | Gjerdrum LM, Sorensen BS, Kjeldsen E, et al (2004). Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma: an alternative method for HER-2/neu analysis. J Mol Diagn, 6, 42-51. DOI ScienceOn |
15 | Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN (2007). Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol, 608, 1-22. DOI |
16 | Hurvitz SA, Hu Y, O'Brien N, Finn RS (2013). Current approaches and future directions in the treatment of HER2-positive breast cancer. Cancer Treat Rev, 39, 219-29. DOI ScienceOn |
17 | Jorgensen JT, Moller S, Rasmussen BB, et al (2011). High concordance between two companion diagnostics tests: a concordance study between the HercepTest and the HER2 FISH pharmDx kit. Am J Clin Pathol, 136, 145-51. DOI ScienceOn |
18 | Keyhani E, Muhammadnejad A, Karimlou M (2012). Prevalence of HER-2-positive invasive breast cancer: a systematic review from Iran. Asian Pac J Cancer Prev, 13, 5477-82. 과학기술학회마을 DOI ScienceOn |
19 | Kostopoulou E, Vageli D, Kaisaridou D, et al (2007). Comparative evaluation of non-informative HER-2 immunoreactions (2+) in breast carcinomas with FISH, CISH and QRT-PCR. Breast, 16, 615-24. DOI ScienceOn |
20 | Lyng MB, Laenkholm A-V, Pallisgaard N, Ditzel HJ (2008). Identification of genes for normalization of real-time RT-PCR data in breast carcinomas. BMC Cancer, 8, 20. DOI ScienceOn |
21 | Masood S (2006). Raising the bar: a plea for standardization and quality improvement in the practice of breast pathology. Breast J, 12, 409-12. DOI ScienceOn |
22 | Mass RD, Press MF, Anderson S, et al (2005). Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer, 6, 240-6. DOI ScienceOn |
23 | Moelans CB, de Weger RA, Ezendam C, van Diest PJ (2009). HER-2/neu amplification testing in breast cancer by Multiplex Ligation-dependent Probe Amplification: influence of manual- and laser microdissection. BMC Cancer, 9, 4. DOI ScienceOn |
24 | O'Malley FP, Parkes R, Latta E, et al (2001). Comparison of HER2/neu status assessed by quantitative polymerase chain reaction and immunohistochemistry. Am J Clin Pathol, 115, 504-11. DOI ScienceOn |
25 | Perez EA, Suman VJ, Davidson NE, et al (2006). HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol, 24, 3032-8. DOI ScienceOn |
26 |
Pfaffl MW, HorganGW, Dempfle L(2002). Relative expression software tool |
27 | Ramakers C, Ruijter JM, Deprez RHL, Moorman AF (2003). Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. Neuroscience letters, 339, 62-6. DOI ScienceOn |
28 | Ruijter J, Ramakers C, Hoogaars W, et al (2009). Amplification efficiency: linking baseline and bias in the analysis of quantitative PCR data. Nucleic acids Res, 37, 45. DOI ScienceOn |
29 | Rosa FE, Silveira SM, Silveira CGT, et al (2009). Quantitative real-time RT-PCR and chromogenic in situ hybridization: precise methods to detect HER-2 status in breast carcinoma. BMC Cancer, 9, 90. DOI ScienceOn |
30 | Ross JS, Slodkowska EA, Symmans WF, et al (2009). The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist, 14, 320-68. DOI ScienceOn |
31 | Sauter G, Lee J, Bartlett JMS, Slamon DJ, Press MF (2009). Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol, 27, 1323-33. DOI ScienceOn |
32 | Schnitt SJ, Jacobs TW (2001). Current Status of HER2 testing caught between a rock and a hard place. Am J Clin Pathol, 116, 806-10. DOI ScienceOn |
33 | Siegel R, Naishadham D, Jemal A (2013). Cancer statistics, 2013. CA Cancer J Clin, 63, 11-30. DOI ScienceOn |
34 | Tawfik OW, Kimler BF, Davis M, et al (2006). Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma. Histopathol, 48, 258-67. DOI ScienceOn |
35 | Valabrega G, Montemurro F, Aglietta M (2007). Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol, 18, 977-84. DOI ScienceOn |
36 | Zhao H, Langerod A, Ji Y, et al (2004). Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol Biol Cell, 15, 2523-36. DOI ScienceOn |
37 | Vanden Bempt I, Vanhentenrijk V, Drijkoningen M, et al (2005). Real-time reverse transcription-PCR and fluorescence insitu hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas. Histopathol, 46, 431-41. DOI ScienceOn |
38 | Wang S, Saboorian MH, Frenkel EP, et al (2001). Assessment of HER-2/neu status in breast cancer. Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard. Am J Clin Pathol, 116, 495-503. DOI ScienceOn |
39 | Wolff AC, Hammond MEH, Schwartz JN, et al (2007). American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med, 131, 18-43. |
![]() |